AP646A - Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. - Google Patents

Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. Download PDF

Info

Publication number
AP646A
AP646A APAP/P/1997/001092A AP9701092A AP646A AP 646 A AP646 A AP 646A AP 9701092 A AP9701092 A AP 9701092A AP 646 A AP646 A AP 646A
Authority
AP
ARIPO
Prior art keywords
fumagillol
preparation
fumagillin
drugs
ester
Prior art date
Application number
APAP/P/1997/001092A
Other languages
English (en)
Other versions
AP9701092A0 (en
Inventor
Jean-Michel Molina
Francis Deriyubm
Original Assignee
Sanofi Synthelabo
Hopitaux Paris Assist Publique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo, Hopitaux Paris Assist Publique filed Critical Sanofi Synthelabo
Publication of AP9701092A0 publication Critical patent/AP9701092A0/xx
Application granted granted Critical
Publication of AP646A publication Critical patent/AP646A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/1997/001092A 1995-03-27 1996-03-26 Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. AP646A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9503549 1995-03-27
PCT/FR1996/000448 WO1996030010A2 (fr) 1995-03-27 1996-03-26 Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales

Publications (2)

Publication Number Publication Date
AP9701092A0 AP9701092A0 (en) 1997-10-31
AP646A true AP646A (en) 1998-04-27

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001092A AP646A (en) 1995-03-27 1996-03-26 Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections.

Country Status (25)

Country Link
US (1) US5900431A (enExample)
EP (1) EP0817626B1 (enExample)
JP (1) JP3260378B2 (enExample)
KR (1) KR100286920B1 (enExample)
CN (1) CN1072485C (enExample)
AP (1) AP646A (enExample)
AT (1) ATE172641T1 (enExample)
AU (1) AU706161B2 (enExample)
CA (1) CA2216623C (enExample)
CZ (1) CZ286821B6 (enExample)
DE (1) DE69600879T2 (enExample)
DK (1) DK0817626T3 (enExample)
EA (1) EA000150B1 (enExample)
ES (1) ES2128846T3 (enExample)
FR (1) FR06C0014I2 (enExample)
HU (1) HU224028B1 (enExample)
IS (1) IS2048B (enExample)
NO (1) NO315968B1 (enExample)
NZ (1) NZ304906A (enExample)
OA (1) OA10515A (enExample)
PL (1) PL183378B1 (enExample)
SK (1) SK283883B6 (enExample)
TR (1) TR199701048T1 (enExample)
UA (1) UA41446C2 (enExample)
WO (1) WO1996030010A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2216623C (en) * 1995-03-27 2005-05-31 Sanofi Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
WO2000050084A1 (fr) * 1999-02-26 2000-08-31 Sanofi-Synthelabo Formulation stable contenant de la fumagilline
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
CA2706914A1 (en) * 2007-11-28 2009-06-11 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
CA2731020A1 (en) * 2008-07-18 2010-01-21 Zafgen, Inc. Use of antiangiogenic fumagillins in the treatment of obesity
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
EP2486004B1 (en) 2009-10-09 2017-05-03 Zafgen, Inc. Sulphone compounds for use in the treatment of obesity
EP2521719B1 (en) 2010-01-08 2015-07-29 Zafgen, Inc. Fumagillol type compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
CA2806221A1 (en) 2010-07-22 2012-01-26 Zafgen, Inc. Tricyclic compounds and methods of making and using same
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
JP2013543899A (ja) 2010-11-29 2013-12-09 ザフゲン，インコーポレイテッド ６−ｏ−（４−ジメチルアミノエトキシ）シンナモイルフマギロールの非連日投与を用いた肥満の治療
EP2668169B1 (en) 2011-01-26 2017-11-15 Zafgen, Inc. Tetrazole compounds and methods of making and using same
CN103534244B (zh) 2011-03-08 2016-10-12 扎夫根股份有限公司 氧杂螺[2.5]辛烷衍生物及类似物
MX343687B (es) 2011-05-06 2016-11-16 Zafgen Inc Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.
BR112013028666A2 (pt) 2011-05-06 2017-08-08 Zafgen Inc compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
EP2705030B1 (en) 2011-05-06 2016-07-27 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
WO2013109735A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
EP2847176A1 (en) 2012-05-07 2015-03-18 Zafgen, Inc. Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same
EP2846792B1 (en) 2012-05-08 2018-08-15 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
CA2873574A1 (en) 2012-05-09 2013-11-14 Zafgen, Inc. Fumagillol type compounds and methods of making and using same
US9868717B2 (en) 2012-11-05 2018-01-16 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
AU2013337287B2 (en) 2012-11-05 2017-03-23 Zafgen, Inc. Methods of treating liver diseases
US10174009B2 (en) 2012-11-05 2019-01-08 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
MX362391B (es) 2013-03-14 2019-01-15 Zafgen Inc Métodos de tratamiento de enfermedad renal y otros trastornos.
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019946A1 (en) * 1993-03-01 1994-09-15 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
JPH06504262A (ja) * 1990-07-27 1994-05-19 レブリゲン　コーポレーション 脈管形成性の病気の処置用の新規な方法と組成物
CA2216623C (en) * 1995-03-27 2005-05-31 Sanofi Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019946A1 (en) * 1993-03-01 1994-09-15 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin

Also Published As

Publication number Publication date
CA2216623C (en) 2005-05-31
CA2216623A1 (en) 1996-10-03
PL322470A1 (en) 1998-02-02
CN1072485C (zh) 2001-10-10
ES2128846T3 (es) 1999-05-16
NZ304906A (en) 1999-06-29
EP0817626B1 (fr) 1998-10-28
HUP9801220A2 (hu) 1999-09-28
FR06C0014I2 (enExample) 2006-12-29
CN1179715A (zh) 1998-04-22
JP3260378B2 (ja) 2002-02-25
PL183378B1 (pl) 2002-06-28
ATE172641T1 (de) 1998-11-15
NO974466D0 (no) 1997-09-26
AU5278696A (en) 1996-10-16
EP0817626A2 (fr) 1998-01-14
IS4557A (is) 1997-09-11
EA000150B1 (ru) 1998-10-29
US5900431A (en) 1999-05-04
AU706161B2 (en) 1999-06-10
CZ286821B6 (en) 2000-07-12
DK0817626T3 (da) 1999-07-12
TR199701048T1 (xx) 1998-01-21
EA199700267A1 (ru) 1998-04-30
FR06C0014I1 (enExample) 2006-11-17
JPH11506421A (ja) 1999-06-08
AP9701092A0 (en) 1997-10-31
KR100286920B1 (ko) 2001-04-16
MX9707150A (es) 1998-07-31
NO974466L (no) 1997-09-26
KR19980703271A (ko) 1998-10-15
UA41446C2 (uk) 2001-09-17
DE69600879D1 (de) 1998-12-03
IS2048B (is) 2005-09-15
HUP9801220A3 (en) 2001-10-29
DE69600879T2 (de) 1999-06-02
SK130797A3 (en) 1998-03-04
SK283883B6 (sk) 2004-04-06
CZ304997A3 (en) 1997-12-17
OA10515A (fr) 2002-04-24
HU224028B1 (hu) 2005-05-30
WO1996030010A3 (fr) 1996-11-28
NO315968B1 (no) 2003-11-24
WO1996030010A2 (fr) 1996-10-03

Similar Documents

Publication Publication Date Title
AP646A (en) Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections.
US5348744A (en) Antidiarrheal compositions containing loperamide hydrochloride and a saccharide
US4101647A (en) Oral dosage form for X-ray contrast media containing a pharmaceutically acceptable base and method of use thereof
AU608853B2 (en) Inhibitors of glycoprotein processing having anti- retroviral activity
EP0190851B1 (en) Improved antiinflammatory composition
JPH0610141B2 (ja) エイズウイルス性疾患処置剤
US4895851A (en) Use of oxoquinazoline derivatives in the treatment of hyperuricaemia
MXPA97007150A (en) Use of fumagilol and its derivatives to prepare medicines intended to combat intestine infections
AU748883B2 (en) Method of treating pulmonary hypertension
US6593329B1 (en) Method for the treatment or prevention of coronary graft vasospasm
WO1994005300B1 (en) Use of rapamycin in the treatment of aids
EP0555302A1 (en) Method of treating demyelinating disease
US7485642B2 (en) Method for treating septic shock
EP0402477B1 (en) Use of isocarbacyclins for preventing or treating organ diseases
JPH0132804B2 (enExample)
JPH04266822A (ja) システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
US20070093519A1 (en) Anti-emetic uses of cannabinoid analogs
US20040044016A1 (en) Antiviral agents
JPS58210010A (ja) 抗腫瘍剤
JPH02174721A (ja) 脂質低下剤
JPH0899883A (ja) 膵炎治療剤